Amercian doctors support FDA decision on Adderall

The American Association of Child & Adolescent Psychiatry (AACAP), the professional medical association dedicated to treating and improving the quality of life for children, adolescents, and families affected by mental, behavioral, or developmental disorders, seems to agree with the US FDA on Adderall recall decision, that is, sufficient data is just not there to show that the recent deaths have occured due to Adderall.

In the meantime, AACAP is advising its members that they include a thorough psychiatric and medical history in the context of a comprehensive evaluation when a child presents with symptoms for ADHD or any other disorder and discuss the newly available risks with the parents. It is also suggesting that patients be monitored more carefully.

Related articles:

Shire expects Adderall decision reversal

FDA must recall Adderall till complete risk analysis is done